Positive phase 2 study results typically lead to increased investor confidence, potentially driving up the stock price in the short term. Given the significance of cardiovascular diseases globally and the innovative approach of targeting Lp(a) levels, these results could significantly impact Silence Therapeutics' valuation and investor interest.